Furthermore, a combined 27% of participants who had genetic testing reported a mutation in BRCA1 (12%), BRCA2 (7%) or in another OC gene (8%; most commonly RAD51C/D, CHEK2 and the Lynch Syndrome genes). This evidence concerns the gene CHEK2 and Lynch syndrome.